Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2019; 9(25):7772-7791. doi:10.7150/thno.34941 This issue Cite

Review

Theranostics in immuno-oncology using nanobody derivatives

Quentin Lecocq1, Yannick De Vlaeminck1, Heleen Hanssens2, Matthias D'Huyvetter2, Geert Raes3,4, Cleo Goyvaerts1, Marleen Keyaerts2,5, Nick Devoogdt2✉, Karine Breckpot1✉

1. Laboratory for Molecular and Cellular Therapy (LMCT), Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, B-1090 Brussels
2. In Vivo Cellular and Molecular Imaging Laboratory (ICMI), VUB, Laarbeeklaan 103, B-1090 Brussels
3. Unit of Cellular and Molecular Immunology (CMIM), VUB, Pleinlaan 2, B-1050 Brussels
4. Myeloid Cell Immunology Lab, VIB Inflammation Research Center, Pleinlaan 2, B-1050 Brussels, Belgium
5. Nuclear Medicine Department, UZ Brussel, Laarbeeklaan 101, B-1090 Brussels.
* These authors share senior authorship

✉ Corresponding authors: Karine Breckpot: Tel: 0032-2-477.45.65, Mail: karine.breckpotbe; Nick Devoogdt: Tel: 0032-2-477.49.91, Mail: ndevoogdbe

Citation:
Lecocq Q, De Vlaeminck Y, Hanssens H, D'Huyvetter M, Raes G, Goyvaerts C, Keyaerts M, Devoogdt N, Breckpot K. Theranostics in immuno-oncology using nanobody derivatives. Theranostics 2019; 9(25):7772-7791. doi:10.7150/thno.34941. https://www.thno.org/v09p7772.htm
Other styles

File import instruction

Abstract

Graphic abstract

Targeted therapy and immunotherapy have become mainstream in cancer treatment. However, only patient subsets benefit from these expensive therapies, and often responses are short‐lived or coincide with side effects. A growing modality in precision oncology is the development of theranostics, as this enables patient selection, treatment and monitoring. In this approach, labeled compounds and an imaging technology are used to diagnose patients and select the best treatment option, whereas for therapy, related compounds are used to target cancer cells or the tumor stroma. In this context, nanobodies and nanobody-directed therapeutics have gained interest. This interest stems from their high antigen specificity, small size, ease of labeling and engineering, allowing specific imaging and design of therapies targeting antigens on tumor cells, immune cells as well as proteins in the tumor environment. This review provides a comprehensive overview on the state-of-the-art regarding the use of nanobodies as theranostics, and their importance in the emerging field of personalized medicine.

Keywords: single domain antibody, nanobody, cancer, molecular imaging, immunotherapy

Citation styles

APA
Lecocq, Q., De Vlaeminck, Y., Hanssens, H., D'Huyvetter, M., Raes, G., Goyvaerts, C., Keyaerts, M., Devoogdt, N., Breckpot, K. (2019). Theranostics in immuno-oncology using nanobody derivatives. Theranostics, 9(25), 7772-7791. https://doi.org/10.7150/thno.34941.

ACS
Lecocq, Q.; De Vlaeminck, Y.; Hanssens, H.; D'Huyvetter, M.; Raes, G.; Goyvaerts, C.; Keyaerts, M.; Devoogdt, N.; Breckpot, K. Theranostics in immuno-oncology using nanobody derivatives. Theranostics 2019, 9 (25), 7772-7791. DOI: 10.7150/thno.34941.

NLM
Lecocq Q, De Vlaeminck Y, Hanssens H, D'Huyvetter M, Raes G, Goyvaerts C, Keyaerts M, Devoogdt N, Breckpot K. Theranostics in immuno-oncology using nanobody derivatives. Theranostics 2019; 9(25):7772-7791. doi:10.7150/thno.34941. https://www.thno.org/v09p7772.htm

CSE
Lecocq Q, De Vlaeminck Y, Hanssens H, D'Huyvetter M, Raes G, Goyvaerts C, Keyaerts M, Devoogdt N, Breckpot K. 2019. Theranostics in immuno-oncology using nanobody derivatives. Theranostics. 9(25):7772-7791.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use